Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!
YANG Jiao, CHEN Junjun, ZHANG Xiangqi, ZHANG Jingxian, HAN Yonglong. Antitumor activity of Xiaoaiping injection combined with paclitaxel on ovarian cancer SK-OV-3 cells and nude mouse with ovarian cancer SK-OV-3 transplantation tumor[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(6): 516-519,529. doi: 10.3969/j.issn.1006-0111.2017.06.009
Citation:
YANG Jiao, CHEN Junjun, ZHANG Xiangqi, ZHANG Jingxian, HAN Yonglong. Antitumor activity of Xiaoaiping injection combined with paclitaxel on ovarian cancer SK-OV-3 cells and nude mouse with ovarian cancer SK-OV-3 transplantation tumor[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(6): 516-519,529. doi: 10.3969/j.issn.1006-0111.2017.06.009
Antitumor activity of Xiaoaiping injection combined with paclitaxel on ovarian cancer SK-OV-3 cells and nude mouse with ovarian cancer SK-OV-3 transplantation tumor
Sixth People's Hospital East Branch Affiliated to Shanghai College of Medicine & Health Sciences, 201306 Shanghai, China
Received Date: 2017-01-04
Rev Recd Date:
2017-05-19
Abstract
Objective To investigate the inhibitory effect of Xiaoaiping injection (XAP) combined with paclitaxel (PTX) on human ovarian cancer SK-OV-3 cells. MethodsIn vitro anti-proliferation activity study of XAP combined with PTX on human ovarian cancer SK-OV-3 cells was performed using optical microscope and MTT assay. Human ovarian cancer SK-OV-3 cells were treated with PTX,XAP,PTX combined XAP or vehicle control.Each group of cells was treated with drugs for 24 h or 48 h.SK-OV-3 cell morphology was observed with optical microscope. MTT assay was used to detect the A value and cell viability was calculated. In vivo effect of XAP combined with PTX on the growth of SK-OV-3 cells was determined in nude mice. In our study, thirty-six mice were randomly divided into six groups:G1 (NS), G2 (PTX, 10 mg/kg), G3 (XAP, 20 ml/kg), G4 (XAP, 50 ml/kg), G5 (PTX 10 mg/kg+XAP 20 ml/kg) and G6 (PTX 10 mg/kg+XAP 50 ml/kg). Animals were treated for 18 days. Body weight, tumor volume and tumor inhibition rate were recorded and calculated. The results were analyzed by the SPSS 19.0 software. ResultsIn vitro study showed that SK-OV-3 cell viability decreased significantly in PTX combined XAP group compared to PTX group or XAP group, in a time and dose-dependent manner. In vivo study showed that the combination of PTX and XAP resulted in decreased tumor weight significantly compared to the control or the PTX alone. Conclusion The combination of XAP and paclitaxel exhibited a synergistic effect both in vitro and in vivo in nude mouse tumor xenograft model.
Cowden Dahl K, Bobbs A, Cole J, et al. Emerging and evolving ovarian cancer animal models[J]. Cancer Growth Metast, 2015, 8(Suppl 1):29-36.
[2]
Shireen R, Brennan D, Flannelly G, et al. Survival in women with ovarian cancer before and after the introduction of adjuvant paclitaxel; a 25-year, single institution review[J]. Ir Med J, 2012, 105(2):47-50.
Harris JW, Rahman A, Kim BR, et al. Metabolism of taxol by human hepatic microsomes and liver slices:participation of cytochrome P4503A4 and an unknown P450 enzyme[J]. Cancer Res, 1994, 54(15):4026-4035.
[6]
Backman JT, Filppula AM, Niemi M, et al.Role of Cytochrome P4502C8 in drug metabolism and interactions[J]. Pharmacol Rev, 2016, 68(1):168-241.
[7]
Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine[J]. Proc Natl Acad Sci USA, 1997, 94(5):2031-2035.
[8]
Crommentuyn KM, Schellens JH, van den Berg JD, et al. In-vitro metabolism of anti-cancer drugs, methods and applications:paclitaxel, docetaxel, tamoxifen and ifosfamide[J]. Cancer Treat Rev, 1998, 24(5):345-366.
Antitumor activity of Xiaoaiping injection combined with paclitaxel on ovarian cancer SK-OV-3 cells and nude mouse with ovarian cancer SK-OV-3 transplantation tumor
Abstract: Objective To investigate the inhibitory effect of Xiaoaiping injection (XAP) combined with paclitaxel (PTX) on human ovarian cancer SK-OV-3 cells. MethodsIn vitro anti-proliferation activity study of XAP combined with PTX on human ovarian cancer SK-OV-3 cells was performed using optical microscope and MTT assay. Human ovarian cancer SK-OV-3 cells were treated with PTX,XAP,PTX combined XAP or vehicle control.Each group of cells was treated with drugs for 24 h or 48 h.SK-OV-3 cell morphology was observed with optical microscope. MTT assay was used to detect the A value and cell viability was calculated. In vivo effect of XAP combined with PTX on the growth of SK-OV-3 cells was determined in nude mice. In our study, thirty-six mice were randomly divided into six groups:G1 (NS), G2 (PTX, 10 mg/kg), G3 (XAP, 20 ml/kg), G4 (XAP, 50 ml/kg), G5 (PTX 10 mg/kg+XAP 20 ml/kg) and G6 (PTX 10 mg/kg+XAP 50 ml/kg). Animals were treated for 18 days. Body weight, tumor volume and tumor inhibition rate were recorded and calculated. The results were analyzed by the SPSS 19.0 software. ResultsIn vitro study showed that SK-OV-3 cell viability decreased significantly in PTX combined XAP group compared to PTX group or XAP group, in a time and dose-dependent manner. In vivo study showed that the combination of PTX and XAP resulted in decreased tumor weight significantly compared to the control or the PTX alone. Conclusion The combination of XAP and paclitaxel exhibited a synergistic effect both in vitro and in vivo in nude mouse tumor xenograft model.
YANG Jiao, CHEN Junjun, ZHANG Xiangqi, ZHANG Jingxian, HAN Yonglong. Antitumor activity of Xiaoaiping injection combined with paclitaxel on ovarian cancer SK-OV-3 cells and nude mouse with ovarian cancer SK-OV-3 transplantation tumor[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(6): 516-519,529. doi: 10.3969/j.issn.1006-0111.2017.06.009
Citation:
YANG Jiao, CHEN Junjun, ZHANG Xiangqi, ZHANG Jingxian, HAN Yonglong. Antitumor activity of Xiaoaiping injection combined with paclitaxel on ovarian cancer SK-OV-3 cells and nude mouse with ovarian cancer SK-OV-3 transplantation tumor[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(6): 516-519,529. doi: 10.3969/j.issn.1006-0111.2017.06.009
Cowden Dahl K, Bobbs A, Cole J, et al. Emerging and evolving ovarian cancer animal models[J]. Cancer Growth Metast, 2015, 8(Suppl 1):29-36.
[2]
Shireen R, Brennan D, Flannelly G, et al. Survival in women with ovarian cancer before and after the introduction of adjuvant paclitaxel; a 25-year, single institution review[J]. Ir Med J, 2012, 105(2):47-50.
Harris JW, Rahman A, Kim BR, et al. Metabolism of taxol by human hepatic microsomes and liver slices:participation of cytochrome P4503A4 and an unknown P450 enzyme[J]. Cancer Res, 1994, 54(15):4026-4035.
[6]
Backman JT, Filppula AM, Niemi M, et al.Role of Cytochrome P4502C8 in drug metabolism and interactions[J]. Pharmacol Rev, 2016, 68(1):168-241.
[7]
Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine[J]. Proc Natl Acad Sci USA, 1997, 94(5):2031-2035.
[8]
Crommentuyn KM, Schellens JH, van den Berg JD, et al. In-vitro metabolism of anti-cancer drugs, methods and applications:paclitaxel, docetaxel, tamoxifen and ifosfamide[J]. Cancer Treat Rev, 1998, 24(5):345-366.
YANG Jiao, CHEN Junjun, ZHANG Xiangqi, ZHANG Jingxian, HAN Yonglong. Antitumor activity of Xiaoaiping injection combined with paclitaxel on ovarian cancer SK-OV-3 cells and nude mouse with ovarian cancer SK-OV-3 transplantation tumor[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(6): 516-519,529. doi: 10.3969/j.issn.1006-0111.2017.06.009
YANG Jiao, CHEN Junjun, ZHANG Xiangqi, ZHANG Jingxian, HAN Yonglong. Antitumor activity of Xiaoaiping injection combined with paclitaxel on ovarian cancer SK-OV-3 cells and nude mouse with ovarian cancer SK-OV-3 transplantation tumor[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(6): 516-519,529. doi: 10.3969/j.issn.1006-0111.2017.06.009
DownLoad: